Details of the Drug

General Information of Drug (ID: DMIJATC)

Drug Name
Benzphetamine
Synonyms
Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 239.35
Topological Polar Surface Area (xlogp) 4.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 16 - 31 hours [2]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 10.44436 micromolar/kg/day [4]
Chemical Identifiers
Formula
C17H21N
IUPAC Name
(2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine
Canonical SMILES
C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2
InChI
InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
InChIKey
YXKTVDFXDRQTKV-HNNXBMFYSA-N
Cross-matching ID
PubChem CID
5311017
ChEBI ID
CHEBI:3044
CAS Number
156-08-1
DrugBank ID
DB00865
TTD ID
D0T5UL
INTEDE ID
DR0198
ACDINA ID
D00063

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [7]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Substrate [8]
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DEIZLTN CP4FB_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Benzphetamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Benzphetamine caused by Sodium bicarbonate mediated altered urine pH. Acidosis [5C73] [47]
Tromethamine DMOBLGK Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Benzphetamine caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [47]
Methylene blue DMJAPE7 Major Increased risk of hyperpyrexia by the combination of Benzphetamine and Methylene blue. Acquired methaemoglobinaemia [3A93] [48]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Benzphetamine and Droxidopa. Autonomic nervous system disorder [8D87] [49]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Benzphetamine and Ethanol. Cystitis [GC00] [50]
Selegiline DM6034S Major Increased risk of hyperpyrexia by the combination of Benzphetamine and Selegiline. Depression [6A70-6A7Z] [48]
Isocarboxazid DMAF1NB Major Increased risk of hyperpyrexia by the combination of Benzphetamine and Isocarboxazid. Depression [6A70-6A7Z] [48]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Benzphetamine and Esketamine. Depression [6A70-6A7Z] [51]
SODIUM CITRATE DMHPD2Y Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Benzphetamine caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [47]
Procarbazine DMIK367 Major Increased risk of hyperpyrexia by the combination of Benzphetamine and Procarbazine. Hodgkin lymphoma [2B30] [48]
Didanosine DMI2QPE Moderate Decreased absorption of Benzphetamine due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [52]
Sodium acetate anhydrous DMH21E0 Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Benzphetamine caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [47]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Benzphetamine and Polyethylene glycol. Irritable bowel syndrome [DD91] [53]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Benzphetamine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [54]
Ozanimod DMT6AM2 Major Additive hypertensive effects by the combination of Benzphetamine and Ozanimod. Multiple sclerosis [8A40] [48]
Promethazine DM6I5GR Moderate Antagonize the effect of Benzphetamine when combined with Promethazine. Nausea/vomiting [MD90] [55]
Bupropion DM5PCS7 Major Decreased metabolism of Benzphetamine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [56]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Benzphetamine and Rasagiline. Parkinsonism [8A00] [48]
Abametapir DM2RX0I Moderate Decreased metabolism of Benzphetamine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [57]
Lefamulin DME6G97 Moderate Decreased metabolism of Benzphetamine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [58]
Levomepromazine DMIKFEL Moderate Antagonize the effect of Benzphetamine when combined with Levomepromazine. Psychotic disorder [6A20-6A25] [55]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Benzphetamine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [59]
Mesoridazine DM2ZGAN Moderate Antagonize the effect of Benzphetamine when combined with Mesoridazine. Schizophrenia [6A20] [55]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Benzphetamine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [60]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Benzphetamine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [59]
Methdilazine DMAUHQX Moderate Antagonize the effect of Benzphetamine when combined with Methdilazine. Vasomotor/allergic rhinitis [CA08] [55]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Benzphetamine when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [61]
⏷ Show the Full List of 27 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 30 E00456 3000709 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate E00244 15324 lubricant
Crospovidone E00626 Not Available Disintegrant
FD&C red no. 3 E00629 Not Available Colorant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Benzphetamine 50 mg tablet 50 mg Oral Tablet Oral
Benzphetamine 25 mg tablet 25 mg Oral Tablet Oral
Benzphetamine Hydrochloride 50mg tablet 50mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
6 Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
7 Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52.
8 On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
9 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
20 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
21 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
22 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
23 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
24 Drugs that may have potential CYP2B6 interactions.
25 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
26 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
27 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
28 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
29 Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
30 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
31 Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
32 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
33 Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
34 Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
35 Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
36 Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.
37 Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
38 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
39 Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
40 Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
41 The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
42 Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
43 Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
44 Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
45 Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
46 Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
47 Anggard E, Jonsson LE, Hogmark AL, Gunne LM "Amphetamine metabolism in amphetamine psychosis." Clin Pharmacol Ther 14 (1973): 870-80. [PMID: 4729903]
48 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
49 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
50 Product Information. Suprenza (phentermine). Akrimax Pharmaceuticals, Cranford, NJ.
51 Cerner Multum, Inc. "Australian Product Information.".
52 Product Information. Adderall (amphetamine-dextroamphetamine) Shire Richwood Pharmaceutical Company, Florence, KY.
53 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
54 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
56 Canadian Pharmacists Association.
57 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
58 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
59 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
60 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
61 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]